Artelo Biosciences closed at $2.27 on Nov 4, down 5.42%, 97.6% below its 52-week closing high. Volume of 8.5K shares was 0.23× its 20-day average (below normal).
Split-adjusted performance: -34.4% over one month, -90.9% over six months, -97.2% over one year.
Short interest was 34.7K shares at the Oct 15 settlement, down 24.7% from the prior report (0.8% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ARTLArtelo Biosciences | $2.27 | −5.42% | −90.9% | — | — | — | $1.2M | |
| MTNBMatinas BioPharma Holdings | $1.19 | +4.39% | −88.3% | — | — | — | $1.2M | Compare |
| JAGXJaguar Health | $0.4988 | −10.53% | −97.6% | −58.9% | −1036.8% | — | $1.2M | Compare |
| VBIOValion Bio | $0.5171 | −2.60% | — | — | — | — | $1.1M | Compare |
| GOVXGeoVax Labs, Inc. New | $0.1680 | +2.38% | −89.8% | −100.0% | — | — | $1.5M | Compare |
| ELABPMGC Holdings | $1.92 | −1.03% | −91.0% | — | −225.1% | — | $1.6M | Compare |
| KPTIKaryopharm Therapeutics | $0.0729 | −17.44% | −99.2% | −11.9% | −200.5% | — | $1.7M | Compare |
| KAPAKairos Pharma | $0.4897 | −3.03% | −87.4% | — | — | — | $1.7M | Compare |
| OGENOragenics | $0.3720 | +0.51% | −40.0% | — | — | — | $1.7M | Compare |
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
